The FDA approved the first posterior motion-preserving device for degenerative disc disease, while DiscGenics, Angitia, and BioRestorative advanced late-stage trials. ReGelTec reported positive HYDRAFIL data and CE Mark approval.
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07801755 |
Sensory Stimulation Belt for Chronic Low Back Pain in Office Workers |
NOT_YET_RECRUITING | NA |
| NCT07801729 |
Optimization of Lumbar Sensory Stimulation Parameters in Office Workers With Chronic Low Back Pain |
NOT_YET_RECRUITING | NA |
| NCT07053787 |
Durability of Yoga for Veterans With Low Back Pain |
NOT_YET_RECRUITING | NA |
